Double-stranded ribonucleic acid with increased effectiveness in an organism

Details for Australian Patent Application No. 2009201091 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Limmer, Stefan; Hadwiger, Phillip; Vornlocher, Hans-Peter; John, Matthias; Woppmann, Claudia

Agent Griffith Hack

Pub. Number AU-B-2009201091

Parent 2004263830

Filing date 18 March 2009

Wipo publication date 9 April 2009

Acceptance publication date 8 December 2011

International Classifications

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

2 April 2009 Complete Application Filed

9 April 2009 Application Open to Public Inspection

  Published as AU-B-2009201091

8 December 2011 Application Accepted

  Published as AU-B-2009201091

2 February 2012 Corrigenda

  Applications Accepted - Name Index Under the name Alnylam Pharmaceuticals, Inc., Application No. 2009201091 under INID (72) correct the co-inventor to Hadwiger, Phillipp

5 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009201092-Developing device, process cartridge, image forming device, and developer container

2009201090-Bicyclic amides as kinase inhibitors